![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » GENVEC RECEIVES NIAID BIODEFENSE PROGRAM GRANT FOR DEVELOPMENT OF BROADLY APPLICABLE VACCINE TECHNOLOGY
GENVEC RECEIVES NIAID BIODEFENSE PROGRAM GRANT FOR DEVELOPMENT OF BROADLY APPLICABLE VACCINE TECHNOLOGY
GenVec, Inc. announced that it has received a $430,000 Phase I Small Business Innovation Research award from the National Institute of Allergy and Infectious Diseases Biodefense Program to support the company's efforts to develop novel adenovector-based vaccine technology. The funding will support research to advance GenVec's adenovector technology to develop a range of vaccines based on novel serotypes of adenovirus. The new vectors produced under this grant will incorporate influenza genes to assess their improved immunogenicity. BioSpace (http://home.businesswire.com/portal/site/biospace/index.jsp?epi-content=GENERIC&newsId=20060829005381&ndmHsc=v2*A1156244400000*B1156885151000*DgroupByDate*J2*N1000122&newsLang=en&beanID=1229976837&viewID=news_view)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct